|
1
|
ECM-receptor interaction
|
14.5*
|
10/84
|
COL6A1, LAMB2
|
CD44, CD47, FN1, ITGA2, LAMB1, THBS1
|
|
2
|
Adherens junction
|
11.94
|
1/78
| |
MET
|
|
3
|
Haematopoietic cell lineage
|
9.93*
|
8/87
| |
CD44, CD55. CD59, IL1R2, IL4R, IL7R, ITGA2, ITGA6
|
|
4
|
Small cell lung cancer
|
7.96*
|
7/86
|
LAMB2
|
FN1, ITGA2, ITGA6, LAMB1, MYC
|
|
5
|
Basal cell carcinoma
|
7.83
|
2/55
|
WNT10A, WNT4
| |
|
6
|
Pathways in cancer
|
7.27*
|
13/330
|
DAPK2, LAMB2, WNT10A, WNT4
|
ETS1, FN1, ITGA2, ITGA6, LAMB1, MET, MYC, RUNX1
|
|
7
|
Focal adhesion
|
7.02*
|
10/203
|
COL6A1, LAMB2
|
FLNB, FN1, ITGA2, LAMB1, MET, THBS1
|
|
8
|
TGF-beta signalling pathway
|
6.61*
|
5/87
|
INHBB
|
FST, MYC, THBS1, ID1
|
|
9
|
Axon guidance
|
6.48*
|
7/129
|
EFNB3, NFATC4, NTN1, SEMA3C
|
MET, PLXNC1, SRGAP1
|
|
10
|
Jak-STAT signalling pathway
|
6.32*
|
7/155
| |
IL13RA2, IL24, IL4R, IL7R, MYC, OSMR, SOCS3
|
|
11
|
Calcium signalling pathway
|
4.93
|
2/182
| |
EDNRA, HRH1
|
|
12
|
Bladder cancer
|
4.74*
|
3/42
|
DAPK2
|
MYC, THBS1
|
|
13
|
B cell receptor signalling pathway
|
4.62
|
2/65
|
BLNK, NFATC4
| |
|
14
|
Complement and coagulation cascades
|
4.59*
|
4/69
|
C3
|
CD55, CD59, F3
|
|
15
|
Cytokine-cytokine receptor interaction
|
4.56*
|
9/263
|
INHBB
|
CXCL5, IL1R2, IL24, IL4R, IL7R, MET, OSMR, PPBP
|
|
16
|
Regulation of actin cytoskeleton
|
4.37
|
5/217
|
CYFIP2
|
FN1, ITGA2, ITGA6, SSH1
|
|
17
|
Regulation of autophagy
|
4.32
|
1/35
|
GABARAPL1
| |
|
18
|
Melanoma
|
4.25
|
1/71
| |
MET
|
|
19
|
Wnt signaling pathway
|
4.2
|
4/152
|
NFATC4, WNT10A, WNT4
|
MYC
|
|
20
|
Tight junction
|
4.11
|
2/135
|
JAM2, TJP3
| |
